David Gómez-Sánchez

Mr. David Gómez-Sánchez

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2022 in Science Advances
Verified
Journal Article
Open access
CVCarolina Villarroya-Beltri
Carolina Villarroya-Beltri
ACAna Osorio Cabrero
Ana Osorio Cabrero
RTRaul Torres-Ruiz
Raul Torres-Ruiz
DGDavid Gómez-Sánchez
David Gómez-Sánchez
MTMarianna Trakala
Marianna Trakala
MUMiguel Urioste
Miguel Urioste
Germline mutations leading to aneuploidy are rare, and their tumor-promoting properties are mostly unknown at the molecular level. We report here novel germline biallelic mutations in MAD1L1 , encoding the spindle assembly checkpoint (SAC) protein MAD1, in a 36-year-old female with a dozen of neoplasias. Functional studies demonstrated lack of full-length protein and deficient SAC response, resulting in ~30 to 40% of aneuploid blood cells. Single-cell RNA analysis identified mitochondrial stress accompanied by systemic inflammation with enhanced interferon and NFκB signaling both in aneuploid and euploid cells, suggesting a non–cell autonomous response. MAD1L1 mutations resulted in specific clonal expansions of γδ T cells with chromosome 18 gains and enhanced cytotoxic profile as well as intermediate B cells with chromosome 12 gains and transcriptomic signatures characteristic of leukemia cells. These data point to MAD1L1 mutations as the cause of a new variant of mosaic variegated aneuploidy with systemic inflammation and unprecedented tumor susceptibility.

19 March 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
ICIsabel Cuenca
Isabel Cuenca
DADaniel Alameda
Daniel Alameda
BSBeatriz Sanchez-Vega
Beatriz Sanchez-Vega
DGDavid Gómez-Sánchez
David Gómez-Sánchez
DADiego Alignani
Diego Alignani
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez

1 January 2018 in Clinical Lung Cancer
Verified
Journal Article
Closed access
JZJon Zugazagoitia
Jon Zugazagoitia
DRDaniel Rueda
Daniel Rueda
NCNuria Carrizo
Nuria Carrizo
AEAna Belen Enguita
Ana Belen Enguita
DGDavid Gómez-Sánchez
David Gómez-Sánchez
SPSantiago Ponce-Aix
Santiago Ponce-Aix

Verified
Journal Article
Open access
PDF file
JPJavier Ramos Paradas
Javier Ramos Paradas
DGDavid Gómez-Sánchez
David Gómez-Sánchez
ARAranzazu Rosado
Aranzazu Rosado
AUAlvaro Conrado Ucero
Alvaro Conrado Ucero
IFIrene Ferrer
Irene Ferrer
LPLuis Paz-Ares
Luis Paz-Ares
Lung cancer is the leading cause of cancer mortality worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent histology. While immunotherapy with checkpoint inhibitors has shown outstanding results in NSCLC, the precise identification of responders remains a major challenge. Most studies attempting to overcome this handicap have focused on adenocarcinomas or squamous cell carcinomas. Among NSCLC subtypes, the molecular and immune characteristics of lung large cell carcinoma (LCC), which represents 10% of NSCLC cases, are not well defined. We hypothesized that specific molecular aberrations may impact the immune microenvironment in LCC and, consequently, the response to immunotherapy. To that end, it is particularly relevant to thoroughly describe the molecular genotype–immunophenotype association in LCC–to identify robust predictive biomarkers and improve potential benefits from immunotherapy. We established a cohort of 18 early-stage, clinically annotated, LCC cases. Their molecular and immune features were comprehensively characterized by genomic and immune-targeted sequencing panels along with immunohistochemistry of immune cell populations. Unbiased clustering defined two novel subgroups of LCC. Pro-immunogenic tumors accumulated certain molecular alterations, showed higher immune infiltration and upregulated genes involved in potentiating immune responses when compared to pro-tumorigenic samples, which favored tumoral progression. This classification identified a set of biomarkers that could potentially predict response to immunotherapy. These results could improve patient selection and expand potential benefits from immunotherapy.

Verified
Journal Article
Open access
PDF file
ÁMÁngela Marrugal
Ángela Marrugal
IFIrene Ferrer
Irene Ferrer
DGDavid Gómez-Sánchez
David Gómez-Sánchez
AQAlvaro Quintanal
Alvaro Quintanal
MPMaría Dolores Pastor
María Dolores Pastor
Sonia Molina PineloSonia Molina Pinelo
Sonia Molina Pinelo
Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though responses to them have been limited to date. Given the need to maximize treatment efficacy, the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol derivatives). From the protein profiles identified according to response, the relationship between lactate dehydrogenase B (LDHB) and DNA topoisomerase 1 (TOP1) with respect to sensitivity and resistance, respectively, to geldanamycin derivatives is noteworthy. Likewise, rhotekin (RTKN) and decaprenyl diphosphate synthase subunit 2 (PDSS2) were correlated with sensitivity and resistance to radicicol derivatives. We also identified a relationship between resistance to HSP90 inhibition and the p53 pathway by glucose deprivation. In contrast, arginine biosynthesis was correlated with sensitivity to HSP90 inhibitors. Further study of these outcomes could enable the development of strategies to improve the clinical efficacy of HSP90 inhibition in patients with lung adenocarcinoma.

28 February 2022 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LPLaura Pena-Couso
Laura Pena-Couso
MEMaría Ercibengoa
María Ercibengoa
FMFátima Mercadillo
Fátima Mercadillo
DGDavid Gómez-Sánchez
David Gómez-Sánchez
LILucía Inglada-Pérez
Lucía Inglada-Pérez
MUMiguel Urioste
Miguel Urioste
Background: The limited knowledge about the PTEN hamartoma tumor syndrome (PHTS) makes its diagnosis a challenging task. We aimed to define the clinical and genetic characteristics of this syndrome in the Spanish population and to identify new genes potentially associated with the disease. Results: We reviewed the clinical data collected through a specific questionnaire in a series of 145 Spanish patients with a phenotypic features compatible with PHTS and performed molecular characterization through several approaches including next generation sequencing and whole exome sequencing (WES). Macrocephaly, mucocutaneous lesions, gastrointestinal polyposis and obesity are prevalent phenotypic features in PHTS and help predict the presence of a PTEN germline variant in our population. We also find that PHTS patients are at risk to develop cancer in childhood or adolescence. Furthermore, we observe a high frequency of variants in exon 1 of PTEN, which are associated with renal cancer and overexpression of KLLN and PTEN. Moreover, WES revealed variants in genes like NEDD4 that merit further research. Conclusions: This study expands previously reported findings in other PHTS population studies and makes new contributions regarding clinical and molecular aspects of PHTS, which are useful for translation to the clinic and for new research lines.